Efundem Nelsy T, Assob Jules Clement N, Feteh Vitalis F, Choukem Simeon-Pierre
Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, Cameroon.
Health and Human Development (2HD) Research Network, Douala, Cameroon.
BMC Res Notes. 2017 Sep 12;10(1):477. doi: 10.1186/s13104-017-2804-5.
Microalbuminuria (MA) is the earliest clinical evidence of diabetic nephropathy, but most patients in sub-Saharan Africa (SSA) only have access to much cheaper dipstick proteinuria as a means to screen for diabetic nephropathy. The aim of this study was to determine the prevalence and associations of MA among proteinuria-negative type 2 diabetic patients in a SSA setting.
In this cross-sectional study, patients with type 2 diabetes screened negative for dipstick proteinuria in a primary healthcare hospital were assessed. Detection of microalbuminuria was carried out in two steps: qualitative detection using special microalbumin urine strip, and quantitative laboratory measurement and calculation of urinary albumin-to-creatinine ratio (UACR). Microalbuminuria was defined as UACR of 30-300 mg/g.
A total of 162 type 2 diabetic patients were included. Using quantitative assessment, the prevalence of microalbuminuria was 14.2% (95% CI 8.8-19.6) whereas 26.5% (95% CI 19.8-34.0) had microalbuminuria with urine strip. The mean systolic blood pressure (p = 0.032), diastolic blood pressure (p = 0.032) and serum creatinine concentration (p < 0.001) were higher in people with microalbuminuria as compared to those with normoalbuminuria, whereas the mean body mass index (p = 0.046) and mean eGFR (p < 0.001) were lower in the albuminuria group. In multiple linear regression, eGFR (p = 0.001) and serum creatinine concentration (p = 0.003) were independently associated with increased UACR.
One in every seven proteinuria-negative type 2 diabetic patients has microalbuminuria in primary care setting in Cameroon; microalbuminuria is associated with higher systolic and diastolic blood pressure, and declining kidney function. Our results emphasize the urgent need to increase the accessibility to microalbuminuria testing to ensure that all diabetic patients with negative dipstick proteinuria can benefit.
微量白蛋白尿(MA)是糖尿病肾病最早的临床证据,但撒哈拉以南非洲(SSA)的大多数患者只能使用便宜得多的尿试纸蛋白尿检测作为筛查糖尿病肾病的手段。本研究的目的是确定SSA地区蛋白尿阴性的2型糖尿病患者中MA的患病率及其相关因素。
在这项横断面研究中,对一家基层医疗医院中尿试纸蛋白尿筛查为阴性的2型糖尿病患者进行了评估。微量白蛋白尿的检测分两步进行:使用特殊的微量白蛋白尿试纸进行定性检测,以及通过实验室定量测量并计算尿白蛋白与肌酐比值(UACR)。微量白蛋白尿定义为UACR为30 - 300mg/g。
共纳入162例2型糖尿病患者。采用定量评估,微量白蛋白尿的患病率为14.2%(95%CI 8.8 - 19.6),而尿试纸检测显示有微量白蛋白尿的比例为26.5%(95%CI 19.8 - 34.0)。与正常白蛋白尿患者相比,微量白蛋白尿患者的平均收缩压(p = 0.032)、舒张压(p = 0.032)和血清肌酐浓度(p < 0.001)更高,而蛋白尿组的平均体重指数(p = 0.046)和平均估算肾小球滤过率(eGFR)(p < 0.001)更低。在多元线性回归中,eGFR(p = 0.001)和血清肌酐浓度(p = 0.003)与UACR升高独立相关。
在喀麦隆的基层医疗环境中,每七名蛋白尿阴性的2型糖尿病患者中就有一名患有微量白蛋白尿;微量白蛋白尿与更高的收缩压和舒张压以及肾功能下降有关。我们的结果强调迫切需要增加微量白蛋白尿检测的可及性,以确保所有尿试纸蛋白尿阴性的糖尿病患者都能从中受益。